Sherman, Matthew A;
Nicolai, Rebecca;
Datyner, Emily K;
Rosina, Silvia;
Hamilton, Angela;
Ardalan, Kaveh;
Bader-Meunier, Brigitte;
... CARRA, JDM Therapeutics Workgrp PReS JDM Working Party; + view all
(2025)
Approach to Janus kinase inhibition for juvenile dermatomyositis among CARRA and PReS providers.
Rheumatology
, Article keaf086. 10.1093/rheumatology/keaf086.
![[thumbnail of Wilkinson_jaki_manuscript_2024-11-04.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/text.png) |
Text
Wilkinson_jaki_manuscript_2024-11-04.pdf - Accepted Version Access restricted to UCL open access staff until 11 February 2026. Download (350kB) |
|
Text
Wilkinson_jaki_supplementary.pdf - Accepted Version Access restricted to UCL open access staff until 11 February 2026. Download (312kB) |
|
Text
Wilkinson_jaki_supp_data.pdf - Accepted Version Access restricted to UCL open access staff until 11 February 2026. Download (64kB) |
|
Text
Wilkinson_figure1_full_revised copy 2.tiff - Accepted Version Access restricted to UCL open access staff until 11 February 2026. Download (3MB) |
Abstract
OBJECTIVES: Janus kinase inhibition (JAKi) has been proposed as a treatment for idiopathic inflammatory myopathies to target increased interferon signalling. Predominantly retrospective reports have demonstrated effectiveness of JAKi in refractory juvenile dermatomyositis (JDM). However, JAKi remains an off-label treatment for JDM and there may be variation in use worldwide. An international survey was conducted to investigate approaches to JAKi for JDM. METHODS: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Therapeutics workgroup and core members of the Paediatric Rheumatology European Society (PReS) JDM working party devised an electronic survey to assess the use of JAKi in JDM. CARRA and PReS members were invited by email to complete the survey. RESULTS: There were 229 respondents (18%), with 50% from the US and 29% from Europe. 150 had used JAKi for over 450 patients with JDM; among them, 77% noted clinical improvement in most or all patients and 17% reported side effects. The highest ranked perceived barriers to JAKi use were lack of clinical data and inability to obtain insurance approval. The highest ranked clinical indications for starting JAKi were refractory skin disease, refractory muscle disease, inability to wean steroids, and intolerance to other steroid-sparing agents. CONCLUSION: Pediatric rheumatologists use JAKi off-label treatment for refractory JDM. Most providers noted clinical improvement in their patients. Barriers to JAKi use include lack of clinical data and insurance coverage. Clinical trials are needed to provide better data on the efficacy and safety of JAKi.
| Type: | Article |
|---|---|
| Title: | Approach to Janus kinase inhibition for juvenile dermatomyositis among CARRA and PReS providers |
| Location: | England |
| DOI: | 10.1093/rheumatology/keaf086 |
| Publisher version: | https://doi.org/10.1093/rheumatology/keaf086 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Janus kinase inhibitors, juvenile dermatomyositis, Life Sciences & Biomedicine, pediatric rheumatology, Rheumatology, Science & Technology |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Infection, Immunity and Inflammation Dept |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10208538 |
Archive Staff Only
 |
View Item |
